Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of RAPT Therapeutics, Inc. (NASDAQ: RAPT) (“RAPT”) securities between September 9, 2021 and February 16, 2024.
On February 20, 2024, RAPT issued a press release revealing that the FDA “has verbally notified the company that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma” and that RAPT “expects to receive a formal clinical hold letter from the FDA.” On this news, RAPT’s stock price fell $5.08 per share, or 10.8%, to close at $41.97 per share on February 20, 2024.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.